What is Omeza?
Omeza operates at the intersection of advanced biotechnology and clinical dermatology, specializing in the development of therapies for complex skin conditions. Unlike many modern health-tech firms that prioritize digital platforms, Omeza focuses on the physical science of wound healing, providing healthcare providers with tangible products that support the body's natural repair mechanisms. Its market position is defined by its commitment to restoring skin integrity in patients suffering from chronic wounds, a segment of the healthcare market that remains underserved by traditional pharmaceutical interventions. By focusing on the biological stages of repair, the company provides a unique value proposition that emphasizes clinical efficacy and patient outcomes.
How much funding has Omeza raised?
Omeza has raised a total of $15.8M across 4 funding rounds:
Seed
$7M
Debt
$150K
Debt
$180K
Series A
$8.5M
Seed (2019): $7M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Debt (2021): $180K supported by PPP
Series A (2026): $8.5M featuring BluKap, Florida Opportunity Fund, Astanor Ventures, and Catalyst Fund
Key Investors in Omeza
BluKap
BluKap is a venture capital firm focused on driving innovation in the ocean economy through investments in late seed stages and Series A companies, with a strong emphasis on biotechnology and sustainable business solutions.
Florida Opportunity Fund
Florida Opportunity Fund is dedicated to investing in early-stage companies to enhance Florida's innovation economy, targeting industries such as life sciences and advanced manufacturing.
Astanor Ventures
Astanor Ventures is dedicated to transforming the agrifood and health systems by fostering innovation and impact, backing visionary founders who prioritize sustainability and health.
What's next for Omeza?
With the successful closure of this Series A round, Omeza is well-positioned to scale its operations and expand its clinical footprint. The strategic backing from specialized venture firms suggests a focus on international market penetration and the potential for broader adoption of its regenerative therapies. Moving forward, the company is expected to prioritize clinical validation and the expansion of its product pipeline, ensuring that its solutions remain at the forefront of wound care innovation. As the firm transitions into this next phase of growth, the focus will likely shift toward optimizing supply chain logistics and strengthening its presence within the global healthcare provider network, ultimately aiming to set a new standard for chronic wound treatment.
See full Omeza company page
